ORTEGA-MUNOS Alberto (ES),ОРТЕГА-МУНЬОС Альберто (ES),FAJF Mattyu Kolin Tor (ES),ФАЙФ Маттью Колин Тор (ES),MARTINELL-PEDEMONTE Mark (ES),МАРТИНЕЛЛЬ-ПЕДЕМОНТЕ Марк (ES),TIRAPU-FERNANDES-DE-LA-KUESTA I,ORTEGA-MUNOS Alberto,ОРТЕГА-МУНЬОС Альберто,FAJF Mattyu Kolin Tor,ФАЙФ Маттью Колин Тор,MARTINELL-PEDEMONTE Mark,МАРТИНЕЛЛЬ-ПЕДЕМОНТЕ Марк,TIRAPU-FERNANDES-DE-LA-KUESTA Inigo,ТИРАПУ-ФЕРНАНДЕС-ДЕ-ЛА-КУ
申请号：
RU2013108702
公开号：
RU0002611437C2
申请日:
2011.07.27
申请国别(地区):
RU
年份:
2017
代理人:
摘要：
FIELD: chemistry； pharmaceutics.SUBSTANCE: invention relates to novel compounds of formula (I) or its pharmaceutically acceptable salt or solvate, which have inhibiting activity lysine specific demethylase-1 (LSD1). In compounds of formula (I)(A) means phenyl or pyridyl, where said phenyl or pyridyl comprises n substitutes (R3)； (B) means -O-CH2-phenyl or phenyl, where said phenyl or phenyl fragment, contained in the above -O-CH2-phenyl, comprises n substitutes (R2)； (D) means a monocyclic heteroaryl group containing 5 or 6 ring members, where one to three said ring members are heteroatoms, selected from O, S and N, where said heteroaryl group contains one substitute (R1) and, besides, where said heteroaryl group is covalently bonded to molecules through circular carbon atom； (R1) means -NH2； each (R2) is independently selected from a group comprising C1-C6alkyl, hydroxy group, halogen, C1-C6haloalkyl, C1-C6haloalkyl oxy group or C1-C6alkoxy group； each (R3) is independently selected from a group comprising C1-C6alkyl, a hydroxy group, halogen, C1-C6haloalkyl, C1-C6haloalkyl oxy group or C1-C6alkoxy group； and n independently equal to 0, 1, 2 or 3.EFFECT: compounds can be used for treatment or preventing cancer, selected from a prostate cancer, breast cancer, lung cancer, colorectal cancer, cerebral cancer, blood cancer or leukemia； neurological diseases, including depression, Alzheimer's disease, Huntington's disease, Parkinson's Disease, amyotrophic lateral sclerosis, frontal-temporal dementia or dementia with Lewy bodies； or viral infection caused by herpes virus, or selected from a group of HSV-1, HSV-2, and Epstein-Barr virus.66 cl, 2 tbl, 38 exИзобретение относится к новым соединениям формулы (I) или его фармацевтически приемлемой соли или сольвату, которые обладают активностью ингибитора лизинспецифической деметилазы-1 (LSD1). Соединения могут найти применение для лечения или предупреждения рака, выбранного из рака предстательной железы, рака молочной железы,
